Clinical trials: Replication Repair Deficient
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Trial name
- NCT07644312
- Testing
- Opdualag
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
High Grade Glioma, Replication Repair Deficient
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
This is open label, multicentre, single arm, pilot study of upfront nivolumab in patients with RRD-glioblastoma with favorable immune/genomic biomarkers.
- Trial name
- NCT06519682
- Testing
- Nivolumab, Radiation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Daniel Morgenstern